ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 01:43 UTC
-
New hope for aggressive lymphoma: drug combo trial shows promise
Disease control OngoingThis study tested adding vorinostat to the standard R-CHOP treatment for people with newly diagnosed advanced diffuse large B-cell lymphoma (DLBCL). The goal was to find the safest dose and see if the combination helps keep cancer from coming back. 83 participants received the dr…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
Gene-Guided hope for kids with tough cancers
Knowledge-focused OngoingThis study screens children and young adults (ages 1-21) with advanced solid tumors, lymphomas, or related disorders that have not responded to standard therapy. Researchers analyze the genetic makeup of each patient's tumor to find specific mutations that can be targeted by exis…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 01, 2026 17:58 UTC